OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted biomarker data to the BEST program, added a synthetic control arm, and sought Rolling Review, RMAT and Breakthrough Therapy designations.